EGFR inhibitor · small molecule
BLU-451
0 active trials across 2 of our biomarkers, targeting EGFR exon 20 / atypical. Not approved for any biomarker on marked.bio yet.
Also known as LNG-451.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 0 | 1 | – |
| EGFR exon 20 insertion | 0 | 1 | – |
Trials
0 of 1 trials shown
-
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
BLU-451carboplatinpemetrexed
Documented EGFR mutation, based on Next-generation sequencing (NGS) testing of tumor or liquid biopsy analyzed in …
EGFR exon 19 deletion / L858REGFR exon 20 insertionLung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
No trials match these filters.